Back to top
more

MEI Pharma (MEIP)

(Delayed Data from NSDQ)

$3.03 USD

3.03
23,580

-0.01 (-0.33%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $3.11 +0.08 (2.64%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks News

MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Tops Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0.00% and 34.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEI Pharma, Inc. (MEIP) Reports Break-Even Earnings for Q4

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 100.00% and 95.18%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Mei (MEIP) Begins Phase III Study for B-Cell Malignancies

Mei Pharma (MEIP) doses first patient in phase III study to evaluate zandelisib plus rituximab in follicular lymphoma or marginal zone lymphoma.

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Misses Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -33.33% and -46.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate MEI Pharma, Inc. (MEIP) to Report a Decline in Earnings: What to Look Out for

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -46.67% and 340.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?

MEI Pharma (MEIP) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%

Ampio Pharmaceuticals (AMPE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment

Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.

Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP

Zacks.com featured highlights include: YIN, CALX, OOMA and MEIP

Nitish Marwah headshot

4 Breakout Stocks for Explosive Returns

The first step to selecting the right breakout stock is to calculate its support and resistance level.

Go Defensive to Beat Market Turbulence With These 4 Stocks

Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.

Is the Options Market Predicting a Spike in MEI Pharma (MEIP) Stock?

Investors need to pay close attention to MEI Pharma (MEIP) stock based on the movements in the options market lately.

Kinjel Shah headshot

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.

Sanghamitra Saha headshot

Tap the Solid Momentum in These 5 Solid High-Beta Stocks

Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta stocks that are in high momentum should gain ahead.

How MEI Pharma (MEIP) Stock Stands Out in a Strong Industry

MEI Pharma (MEIP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MEI Pharma, Inc. (MEIP) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in MEI Pharma, Inc. (MEIP).

Top Ranked Momentum Stocks to Buy for May 15th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 15th

The Zacks Analyst Blog Highlights: Ensign, Gaia, MEI Pharma, Turning Point Brands and A10 Networks

The Zacks Analyst Blog Highlights: Ensign, Gaia, MEI Pharma, Turning Point Brands and A10 Networks

Nalak Das headshot

5 Top Stocks That Have Skyrocketed in the Past 7 Days

Despite the coronavirus-induced market downturn, a handful of stocks have soared in the last seven trading days defying the overall market trend.

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

MEI Pharma (MEIP) Catches Eye: Stock Jumps 8.1%

MEI Pharma (MEIP) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.